Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Methylseleninic acid sensitizes prostate cancer to TRAIL-mediated apoptosis
October 25th, 2005
Researchers claim methylseleninic acid (MSA) sensitizes prostate cancer to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. According to recent research published in the journal Oncogene, "TRAIL is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Unfortunately, some tumor cells remain resistant to TRAIL." "Therefore, agents that sensitize malignant cells to TRAIL-mediated cell death might be of particular importance for the development of novel antitumor therapeutic regimens. Recent studies establish a critical role of selenium in prostate cancer prevention in vitro...
Source: Cancer Weekly (2005-10-25)
|
